ReviewStem cell research & therapy2025
HMGB1 as an emerging key modulator of bone remodeling: a narrative review.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Key Inflammatory Pathways, Biomarkers, and Targeted Management Strategies in Primary Total Joint Arthroplasty: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- High Mobility Group Protein B1 Mediates the Role of the Neutrophil Extracellular Traps in the Progression of Acute Myocardial Infarction.Cardiovascular drugs and therapy · 2026Article
- Brain-bone Crosstalk after Neurotrauma: Dual Effects of Traumatic Brain Injury on Skeletal Remodeling.Current osteoporosis reports · 2026Review
- Exogenous HOpen medicine (Warsaw, Poland) · 2026Article
- PBX1 promotes osteoporosis by upregulating HMGB1 to suppress osteogenic differentiation of bone marrow mesenchymal stem cells.Stem cell research & therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bone is a dynamic tissue that undergoes microdamage and requires remodeling to replace old bone matrix. This process demands a tight coupling between bone resorption and bone formation. Aberrant internal environment can decouple these processes, reducing bone mass and compromising mechanical properties. High mobility group box-1 (HMGB1) is a multifunctional protein binding to advanced glycosylation end product-specific receptor (RAGE) and toll-like receptors (TLRs), regulating DNA repair, cytokine production, inflammation, cell proliferation, programmed cell death (PCD). Extracellular HMGB1 serves not only as a damage-associated molecular pattern (DAMP) that promotes cytokine storms and inflammatory cascade responses but also modulates osteogenesis, osteoclastogenesis and angiogenesis. Under physiological or acute trauma conditions, HMGB1 recruits osteoblasts, osteoclasts, and various immune cells to coordinate inflammation and immune responses, clearing pathogens and promoting bone repair. However, chronic HMGB1 overrelease strengthens osteoclastogenesis and bone resorption, leading to uncoupled bone remodeling and homeostatic imbalance. Thus, HMGB1 plays indispensable roles in bone metabolism and immune regulation. Current research on its involvement in bone remodeling remains incomplete and lacks systematic elucidation. This review aims to bridge this critical knowledge gap and provide a comprehensive reference for future investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.